Anika Therapeutics, Inc. (ANIK)
14.82
-0.13
(-0.87%)
USD |
NASDAQ |
May 19, 16:00
14.82
0.00 (0.00%)
After-Hours: 16:14
Anika Therapeutics Enterprise Value : 183.63M for May 18, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| BioCryst Pharmaceuticals, Inc. | 2.899B |
| Elutia, Inc. | 31.73M |
| Plus Therapeutics, Inc. | 25.69M |
| Perspective Therapeutics, Inc. | 162.12M |
| AVITA Medical, Inc. | 162.81M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.056M |
| Revenue (Quarterly) | 29.61M |
| Total Expenses (Quarterly) | 34.67M |
| EPS Diluted (Quarterly) | -0.3737 |
| Gross Profit Margin (Quarterly) | 64.15% |
| Profit Margin (Quarterly) | -17.07% |
| Earnings Yield | -5.34% |
| Normalized Earnings Yield | -5.342 |